Literature DB >> 33662312

Concomitant Cox-Maze IV and Septal Myectomy in Patients With Hypertrophic Obstructive Cardiomyopathy.

Nadia H Bakir1, Robert M MacGregor1, Ali J Khiabani1, Farah N Musharbash1, Matthew R Schill1, Laurie A Sinn1, Richard B Schuessler1, Spencer J Melby1, Marye J Gleva2, Ralph J Damiano3.   

Abstract

BACKGROUND: In patients with hypertrophic obstructive cardiomyopathy, atrial fibrillation is associated with heart failure and increased late mortality. However, the role of surgical ablation in these patients is not well defined. The aim of this study was to evaluate the efficacy of the concomitant Cox-Maze IV procedure in patients undergoing septal myectomy for hypertrophic obstructive cardiomyopathy.
METHODS: Between 2005 and 2019, 347 patients who underwent septal myectomy at a single institution (Washington University School of Medicine, Barnes-Jewish Hospital, St Louis, MO) were retrospectively reviewed. For patients with hypertrophic obstructive cardiomyopathy and atrial fibrillation who underwent a concomitant Cox-Maze IV procedure, freedom from atrial tachyarrhythmias (ATAs) on or off antiarrhythmic drugs (AADs) was evaluated annually. Predictors of ATA recurrence were identified using Fine-Gray regression, with death as a competing risk.
RESULTS: A total of 42 patients underwent concomitant septal myectomy and Cox-Maze IV procedures. The majority of patients, 69% (29 of 42), had paroxysmal atrial fibrillation with a 2.5-year median duration. Operative mortality was 7% (3 of 42). New York Heart Association functional class was reduced after surgery (P < .01). Rates of freedom from recurrent ATAs at 1- and 5-year intervals were 93% (27 of 29) and 100% (14 of 14), respectively. Rates of freedom from ATAs and AADs were 83% (24 of 29) and 100% (14 of 14) at the same time points, respectively. Increased left atrial diameter predicted first ATA recurrence (P < .01). Cerebrovascular accident risk was lower in patients with atrial fibrillation who underwent concomitant Cox-Maze IV and septal myectomy relative to myectomy only (P = .02).
CONCLUSIONS: Late freedom from ATAs on or off AADs was excellent after Cox-Maze IV and septal myectomy. Although there was a higher than expected rate of perioperative complications, the study results suggest that concomitant surgical ablation should be considered in selected patients with hypertrophic obstructive cardiomyopathy and atrial fibrillation.
Copyright © 2022 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 33662312      PMCID: PMC9536242          DOI: 10.1016/j.athoracsur.2020.12.090

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   5.102


  22 in total

1.  American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines.

Authors:  Barry J Maron; William J McKenna; Gordon K Danielson; Lukas J Kappenberger; Horst J Kuhn; Christine E Seidman; Pravin M Shah; William H Spencer; Paolo Spirito; Folkert J Ten Cate; E Douglas Wigle
Journal:  Eur Heart J       Date:  2003-11       Impact factor: 29.983

2.  2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Bernard J Gersh; Barry J Maron; Robert O Bonow; Joseph A Dearani; Michael A Fifer; Mark S Link; Srihari S Naidu; Rick A Nishimura; Steve R Ommen; Harry Rakowski; Christine E Seidman; Jeffrey A Towbin; James E Udelson; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2011-11-08       Impact factor: 24.094

3.  2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation.

Authors:  Hugh Calkins; Gerhard Hindricks; Riccardo Cappato; Young-Hoon Kim; Eduardo B Saad; Luis Aguinaga; Joseph G Akar; Vinay Badhwar; Josep Brugada; John Camm; Peng-Sheng Chen; Shih-Ann Chen; Mina K Chung; Jens Cosedis Nielsen; Anne B Curtis; D Wyn Davies; John D Day; André d'Avila; N M S Natasja de Groot; Luigi Di Biase; Mattias Duytschaever; James R Edgerton; Kenneth A Ellenbogen; Patrick T Ellinor; Sabine Ernst; Guilherme Fenelon; Edward P Gerstenfeld; David E Haines; Michel Haissaguerre; Robert H Helm; Elaine Hylek; Warren M Jackman; Jose Jalife; Jonathan M Kalman; Josef Kautzner; Hans Kottkamp; Karl Heinz Kuck; Koichiro Kumagai; Richard Lee; Thorsten Lewalter; Bruce D Lindsay; Laurent Macle; Moussa Mansour; Francis E Marchlinski; Gregory F Michaud; Hiroshi Nakagawa; Andrea Natale; Stanley Nattel; Ken Okumura; Douglas Packer; Evgeny Pokushalov; Matthew R Reynolds; Prashanthan Sanders; Mauricio Scanavacca; Richard Schilling; Claudio Tondo; Hsuan-Ming Tsao; Atul Verma; David J Wilber; Teiichi Yamane
Journal:  Heart Rhythm       Date:  2017-05-12       Impact factor: 6.343

4.  Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy.

Authors:  Ethan J Rowin; Anais Hausvater; Mark S Link; Patrick Abt; William Gionfriddo; Wendy Wang; Hassan Rastegar; N A Mark Estes; Martin S Maron; Barry J Maron
Journal:  Circulation       Date:  2017-09-15       Impact factor: 29.690

5.  Concomitant ablation for atrial fibrillation during septal myectomy in patients with hypertrophic obstructive cardiomyopathy.

Authors:  Alexander V Bogachev-Prokophiev; Alexander V Afanasyev; Sergei I Zheleznev; Alexei N Pivkin; Michael S Fomenko; Ravil M Sharifulin; Alexander M Karaskov
Journal:  J Thorac Cardiovasc Surg       Date:  2017-09-01       Impact factor: 5.209

6.  Mid-term outcomes of concomitant surgical ablation of atrial fibrillation in patients undergoing cardiac surgery for hypertrophic cardiomyopathy†.

Authors:  Elisabetta Lapenna; Alberto Pozzoli; Michele De Bonis; Giovanni La Canna; Teodora Nisi; Simona Nascimbene; Luca Vicentini; Stefania Di Sanzo; Benedetto Del Forno; Davide Schiavi; Ottavio Alfieri
Journal:  Eur J Cardiothorac Surg       Date:  2017-06-01       Impact factor: 4.191

Review 7.  The diagnosis and treatment of hypertrophic cardiomyopathy.

Authors:  Christian Prinz; Martin Farr; Detlef Hering; Dieter Horstkotte; Lothar Faber
Journal:  Dtsch Arztebl Int       Date:  2011-04-01       Impact factor: 5.594

8.  2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).

Authors:  Perry M Elliott; Aris Anastasakis; Michael A Borger; Martin Borggrefe; Franco Cecchi; Philippe Charron; Albert Alain Hagege; Antoine Lafont; Giuseppe Limongelli; Heiko Mahrholdt; William J McKenna; Jens Mogensen; Petros Nihoyannopoulos; Stefano Nistri; Petronella G Pieper; Burkert Pieske; Claudio Rapezzi; Frans H Rutten; Christoph Tillmanns; Hugh Watkins
Journal:  Eur Heart J       Date:  2014-08-29       Impact factor: 29.983

9.  Practical recommendations for reporting Fine-Gray model analyses for competing risk data.

Authors:  Peter C Austin; Jason P Fine
Journal:  Stat Med       Date:  2017-09-15       Impact factor: 2.373

10.  The long-term outcomes and durability of the Cox-Maze IV procedure for atrial fibrillation.

Authors:  Ali J Khiabani; Robert M MacGregor; Nadia H Bakir; Joshua L Manghelli; Laurie A Sinn; Hersh S Maniar; Marc R Moon; Richard B Schuessler; Spencer J Melby; Ralph J Damiano
Journal:  J Thorac Cardiovasc Surg       Date:  2020-05-05       Impact factor: 5.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.